{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:52:02Z","timestamp":1793721122794,"version":"4.6.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"20","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Inc. | Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.1038\/s41388-025-03424-x","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:02:49Z","timestamp":1746075769000},"page":"1439-1451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A targeted literature review on the impact of tailored interventions on patient outcomes in oncology"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1760-4697","authenticated-orcid":false,"given":"Graham","family":"Ferrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Filipovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetanjali","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifuddin","family":"Kharawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Mehmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"3424_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","volume":"20","author":"MB Lustberg","year":"2023","unstructured":"Lustberg MB, Kuderer NM, Desai A, Bergerot C, Lyman GH. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol. 2023;20:527\u201342.","journal-title":"Nat Rev Clin Oncol"},{"key":"3424_CR2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","volume":"33","author":"M Di Maio","year":"2022","unstructured":"Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33:878\u201392.","journal-title":"Ann Oncol"},{"key":"3424_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","volume":"17","author":"N Chhabra","year":"2021","unstructured":"Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Toxicol. 2021;17:411\u201324.","journal-title":"J Med Toxicol"},{"key":"3424_CR4","first-page":"1","volume":"3","author":"EH Shinn","year":"2019","unstructured":"Shinn EH, Broderick G, Fellman B, Johnson A, Wieland E, Moulder S, et al. Simulating time-dependent patterns of nonadherence by patients with breast cancer to adjuvant oral endocrine therapy. JCO Clin Cancer Inf. 2019;3:1\u20139.","journal-title":"JCO Clin Cancer Inf"},{"key":"3424_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240864","volume":"13","author":"D Leaning","year":"2023","unstructured":"Leaning D, Kaur G, Morgans AK, Ghouse R, Mirante O, Chowdhury S. Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews. Front Oncol. 2023;13:1240864.","journal-title":"Front Oncol"},{"key":"3424_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10458-x","volume":"23","author":"C Dombeck","year":"2023","unstructured":"Dombeck C, Swezey T, Gonzalez Sepulveda JM, Reeve BB, LeBlanc TW, Chandler D, et al. Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study. BMC Cancer. 2023;23:65.","journal-title":"BMC Cancer"},{"key":"3424_CR7","doi-asserted-by":"publisher","first-page":"8367","DOI":"10.1007\/s00520-022-07283-0","volume":"30","author":"T Kawahara","year":"2022","unstructured":"Kawahara T, Iwamoto T, Takashima I, Hanazawa R, Uemura K, Uemura Y, et al. Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials. Support Care Cancer. 2022;30:8367\u201375.","journal-title":"Support Care Cancer"},{"key":"3424_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s41687-023-00640-5","volume":"7","author":"GA Taarnh\u00f8j","year":"2023","unstructured":"Taarnh\u00f8j GA, Johansen C, Carus A, Dahlrot RH, Dohn LH, Hj\u00f8llund NH, et al. The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial. J Patient Rep. Outcomes. 2023;7:99.","journal-title":"J Patient Rep. Outcomes"},{"key":"3424_CR9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.mcna.2017.06.003","volume":"101","author":"N Gegechkori","year":"2017","unstructured":"Gegechkori N, Haines L, Lin JJ. Long-term and latent side effects of specific cancer types. Med Clin North Am. 2017;101:1053\u201373.","journal-title":"Med Clin North Am"},{"key":"3424_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1200\/JCO.21.01344","volume":"40","author":"W Dai","year":"2022","unstructured":"Dai W, Feng W, Zhang Y, Wang XS, Liu Y, Pompili C, et al. Patient-reported outcome-based symptom management versus usual care after lung cancer surgery: a multicenter randomized controlled trial. J Clin Oncol. 2022;40:988\u201396.","journal-title":"J Clin Oncol"},{"key":"3424_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34:557\u201365.","journal-title":"J Clin Oncol"},{"key":"3424_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.908752","volume":"9","author":"A Carde\u00f1a-Guti\u00e9rrez","year":"2022","unstructured":"Carde\u00f1a-Guti\u00e9rrez A, L\u00f3pez Barahona M. Predictive biomarkers of severe immune-related adverse events with immune checkpoint inhibitors: prevention, underlying causes, intensity, and consequences. Front Med (Lausanne). 2022;9:908752.","journal-title":"Front Med (Lausanne)"},{"key":"3424_CR13","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1158\/1078-0432.CCR-22-0404","volume":"28","author":"P Johannet","year":"2022","unstructured":"Johannet P, Liu W, Fenyo D, Wind-Rotolo M, Krogsgaard M, Mehnert JM, et al. Baseline serum autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade. Clin Cancer Res. 2022;28:4121\u201330.","journal-title":"Clin Cancer Res"},{"key":"3424_CR14","doi-asserted-by":"publisher","first-page":"13217","DOI":"10.1002\/cam4.6013","volume":"12","author":"C Olsson Ladjevardi","year":"2023","unstructured":"Olsson Ladjevardi C, Koliadi A, Ryd\u00e9n V, Inan El-Naggar A, Digkas E, Valachis A, et al. Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study. Cancer Med. 2023;12:13217\u201324.","journal-title":"Cancer Med"},{"key":"3424_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","volume":"109","author":"J Rogado","year":"2019","unstructured":"Rogado J, S\u00e1nchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Lev\u00ed A, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019;109:21\u201327.","journal-title":"Eur J Cancer"},{"key":"3424_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/PROM.S256567","volume":"13","author":"LM Minasian","year":"2022","unstructured":"Minasian LM, O\u2019Mara A, Mitchell SA. Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: using CTCAE and PRO-CTCAE(\u00ae) to provide two distinct and complementary perspectives. Patient Relat Outcome Meas. 2022;13:249\u201358.","journal-title":"Patient Relat Outcome Meas"},{"key":"3424_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103575","volume":"171","author":"S Tamburin","year":"2022","unstructured":"Tamburin S, Park SB, Schenone A, Mantovani E, Hamedani M, Alberti P, et al. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2022;171:103575.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3424_CR18","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.2147\/PPA.S432821","volume":"17","author":"HY Yeo","year":"2023","unstructured":"Yeo HY, Liew AC, Chan SJ, Anwar M, Han CH, Marra CA. Understanding patient preferences regarding the important determinants of breast cancer treatment: A narrative scoping review. Patient Prefer Adherence. 2023;17:2679\u2013706.","journal-title":"Patient Prefer Adherence"},{"key":"3424_CR19","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA). Improving the understanding, acceptance and use of oncology\u2013relevant endpoints in HTA body \/ payer decision-making. 2023. https:\/\/www.efpia.eu\/news-events\/the-efpia-view\/statements-press-releases\/improving-the-understanding-acceptance-and-use-of-oncology-relevant-endpoints-in-hta-body-payer-decision-making."},{"key":"3424_CR20","unstructured":"Fameli A, Paulsson T, Altimari S, Gutierrez B, Cimen A, Nelsen L et al. Looking Beyond Survival Data. How Should We Assess Innovation in Oncology Reimbursement Decision Making. 2023. https:\/\/www.ispor.org\/publications\/journals\/value-outcomes-spotlight\/vos-archives\/issue\/view\/looking-beyond-survival-data-in-oncology-reimbursement-decisions\/looking-beyond-survival-data-how-should-we-assess-innovation-in-oncology-reimbursement-decision-making."},{"key":"3424_CR21","doi-asserted-by":"publisher","first-page":"e076798","DOI":"10.1136\/bmjopen-2023-076798","volume":"14","author":"A Bullen","year":"2024","unstructured":"Bullen A, Ryan M, Ennis H, Gray E, Lor\u00eda-Rebolledo LE, McIntyre M, et al. Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment. BMJ Open. 2024;14:e076798.","journal-title":"BMJ Open"},{"key":"3424_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/OP.21.00466","volume":"18","author":"A Gupta","year":"2022","unstructured":"Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, et al. Financial burden of drugs prescribed for cancer-associated symptoms. JCO Oncol Pr. 2022;18:140\u20137.","journal-title":"JCO Oncol Pr"},{"key":"3424_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/OP.21.00727","volume":"18","author":"F Giap","year":"2022","unstructured":"Giap F, Chino F. What oncologists must account for: the financial burden of cancer-associated symptom relief. JCO Oncol Pr. 2022;18:106\u20138.","journal-title":"JCO Oncol Pr"},{"key":"3424_CR24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40273-013-0081-2","volume":"31","author":"A Carlotto","year":"2013","unstructured":"Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics. 2013;31:753\u201366.","journal-title":"Pharmacoeconomics"},{"key":"3424_CR25","doi-asserted-by":"publisher","first-page":"e243854","DOI":"10.1001\/jamanetworkopen.2024.3854","volume":"7","author":"JD Peipert","year":"2024","unstructured":"Peipert JD, Zhao F, Lee JW, Shen SE, Ip E, O\u2019Connell N, et al. Patient-reported adverse events and early treatment discontinuation among patients with multiple myeloma. JAMA Netw Open. 2024;7:e243854.","journal-title":"JAMA Netw Open"},{"key":"3424_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2023.107567","volume":"173","author":"C Feng","year":"2023","unstructured":"Feng C, Guo Y, Zhang X, Lv C, Li X, Li X. Omni-media health education combined with nanodrug therapy on the creation of gastrointestinal microenvironment and the improvement of treatment compliance in patients with gastrointestinal tumors. Prev Med. 2023;173:107567.","journal-title":"Prev Med"},{"key":"3424_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/curroncol29020067","volume":"29","author":"SD Lambert","year":"2022","unstructured":"Lambert SD, Duncan LR, Culos-Reed SN, Hallward L, Higano CS, Loban E, et al. Feasibility, acceptability, and clinical significance of a Dyadic, web-based, Psychosocial and Physical Activity Self-Management Program (TEMPO) tailored to the needs of men with prostate cancer and their caregivers: a multi-center randomized pilot trial. Curr Oncol. 2022;29:785\u2013804.","journal-title":"Curr Oncol"},{"key":"3424_CR28","doi-asserted-by":"publisher","first-page":"E874","DOI":"10.1097\/NCC.0000000000001030","volume":"45","author":"HR Park","year":"2022","unstructured":"Park HR, Kang HS, Kim SH, Singh-Carlson S. Effect of a smart pill bottle reminder intervention on medication adherence, self-efficacy, and depression in breast cancer survivors. Cancer Nurs. 2022;45:E874\u2013E882.","journal-title":"Cancer Nurs"},{"key":"3424_CR29","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1200\/JCO.20.02015","volume":"39","author":"K Absolom","year":"2021","unstructured":"Absolom K, Warrington L, Hudson E, Hewison J, Morris C, Holch P, et al. Phase III randomized controlled trial of eRAPID: EHealth intervention during chemotherapy. J Clin Oncol. 2021;39:734\u201347.","journal-title":"J Clin Oncol"},{"key":"3424_CR30","doi-asserted-by":"publisher","first-page":"n1647","DOI":"10.1136\/bmj.n1647","volume":"374","author":"R Maguire","year":"2021","unstructured":"Maguire R, McCann L, Kotronoulas G, Kearney N, Ream E, Armes J, et al. Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART). BMJ. 2021;374:n1647.","journal-title":"BMJ"},{"key":"3424_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.breast.2020.03.004","volume":"51","author":"M Fjell","year":"2020","unstructured":"Fjell M, Langius-Ekl\u00f6f A, Nilsson M, Wengstr\u00f6m Y, Sundberg K. Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer \u2013 A randomized controlled trial. Breast. 2020;51:85\u201393.","journal-title":"Breast"},{"key":"3424_CR32","unstructured":"National Institute for Health and Care Excellence (NICE). Critical appraisal of the relevant clinical effectiveness evidence [Internet]. London: National Institute for Health and Care Excellence; [cited 2025 Mar 17]. Available from: National Institute for Health and Care Excellence (NICE). Critical appraisal of the relevant clinical effectiveness evidence [Internet]. London: National Institute for Health and Care Excellence; [cited 2025 Mar 17]. Available from: [2 Clinical effectiveness | Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template | Guidance | NICE."},{"key":"3424_CR33","doi-asserted-by":"publisher","first-page":"e224427","DOI":"10.1001\/jamanetworkopen.2022.4427","volume":"5","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhang X, Shen L, Zhu D, Ma S, Cong L. Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy: a randomized clinical trial. JAMA Netw Open. 2022;5:e224427.","journal-title":"JAMA Netw Open"},{"key":"3424_CR34","doi-asserted-by":"publisher","first-page":"E309","DOI":"10.1097\/NCC.0000000000000948","volume":"45","author":"KM Murphy","year":"2022","unstructured":"Murphy KM, Sauer C, Yang D, Hass N, Novakovic K, Helfand B, et al. The development of iManage-PC, an online symptom monitoring and self-management tool for men with clinically localized prostate cancer. Cancer Nurs. 2022;45:E309\u2013E319.","journal-title":"Cancer Nurs"},{"key":"3424_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11764-018-0682-z","volume":"12","author":"I Graetz","year":"2018","unstructured":"Graetz I, McKillop CN, Stepanski E, Vidal GA, Anderson JN, Schwartzberg LS. Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial. J Cancer Surviv. 2018;12:431\u201340.","journal-title":"J Cancer Surviv"},{"key":"3424_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/cam4.1002","volume":"6","author":"KH Mooney","year":"2017","unstructured":"Mooney KH, Beck SL, Wong B, Dunson W, Wujcik D, Whisenant M, et al. Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT. Cancer Med. 2017;6:537\u201346.","journal-title":"Cancer Med"},{"key":"3424_CR37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jpainsymman.2018.07.021","volume":"56","author":"A Sikorskii","year":"2018","unstructured":"Sikorskii A, Given CW, Given BA, Vachon E, Krauss JC, Rosenzweig M, et al. An automated intervention did not improve adherence to oral oncolytic agents while managing symptoms: results from a two-arm randomized controlled trial. J Pain Symptom Manag. 2018;56:727\u201335.","journal-title":"J Pain Symptom Manag"},{"key":"3424_CR38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00520-019-04865-3","volume":"28","author":"SY Rha","year":"2020","unstructured":"Rha SY, Nam JM, Lee J. Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)\u2014A randomized controlled trial. Support Care Cancer. 2020;28:713\u201323.","journal-title":"Support Care Cancer"},{"key":"3424_CR39","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00520-017-3970-7","volume":"26","author":"NA Kolb","year":"2018","unstructured":"Kolb NA, Smith AG, Singleton JR, Beck SL, Howard D, Dittus K, et al. Chemotherapy-related neuropathic symptom management: a randomized trial of an automated symptom-monitoring system paired with nurse practitioner follow-up. Support Care Cancer. 2018;26:1607\u201315.","journal-title":"Support Care Cancer"},{"key":"3424_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1035-3","volume":"14","author":"LD De Hosson","year":"2019","unstructured":"De Hosson LD, Bouma G, Stelwagen J, Van Essen H, De Bock GH, De Groot DJA, et al. Web-based personalised information and support for patients with a neuroendocrine tumour: Randomised controlled trial. Orphanet J Rare Dis. 2019;14:60.","journal-title":"Orphanet J Rare Dis"},{"key":"3424_CR41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/abm\/kaz067","volume":"54","author":"A Sikorskii","year":"2020","unstructured":"Sikorskii A, Given CW, Given BA, Banik A, Krauss JC. Patient engagement with an automated telephone symptom management intervention: predictors and outcomes. Ann Behav Med. 2020;54:484\u201394.","journal-title":"Ann Behav Med"},{"key":"3424_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41687-022-00414-5","volume":"6","author":"LK Tolstrup","year":"2022","unstructured":"Tolstrup LK, Pappot H, Bastholt L, M\u00f6ller S, Dieperink KB. Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: Health-related quality of life among melanoma patients in a randomized controlled trial. J Patient Rep Outcomes. 2022;6:8.","journal-title":"J Patient Rep Outcomes"},{"key":"3424_CR43","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11764-017-0625-0","volume":"11","author":"RA Willems","year":"2017","unstructured":"Willems RA, Mesters I, Lechner L, Kanera IM, Bolman CAW. Long-term effectiveness and moderators of a web-based tailored intervention for cancer survivors on social and emotional functioning, depression, and fatigue: randomized controlled trial. J Cancer Surviv. 2017;11:691\u2013703.","journal-title":"J Cancer Surviv"},{"key":"3424_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s10916-020-01663-x","volume":"44","author":"TM Rico","year":"2020","unstructured":"Rico TM, Dos Santos Machado K, Fernandes VP, Madruga SW, Santin MM, Petrarca CR, et al. Use of text messaging (SMS) for the management of side effects in cancer patients undergoing chemotherapy treatment: a randomized controlled trial. J Med Syst. 2020;44:193.","journal-title":"J Med Syst"},{"key":"3424_CR45","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/cancers15061775","volume":"15","author":"E Dhar","year":"2023","unstructured":"Dhar E, Bah AN, Chicchi Giglioli IA, Quer S, Fernandez-Luque L, N\u00fa\u00f1ez-Benjumea FJ, et al. A scoping review and a taxonomy to assess the impact of mobile apps on cancer care management. Cancers (Basel). 2023;15:1775.","journal-title":"Cancers (Basel)"},{"key":"3424_CR46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/0269216311402711","volume":"26","author":"CH Chen","year":"2012","unstructured":"Chen CH, Tang ST, Chen CH. Meta-analysis of cultural differences in Western and Asian patient-perceived barriers to managing cancer pain. Palliat Med. 2012;26:206\u201321.","journal-title":"Palliat Med"},{"key":"3424_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11096-020-01141-x","volume":"43","author":"H Adedeji-Adenola","year":"2021","unstructured":"Adedeji-Adenola H, Nlooto M. Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review. Int J Clin Pharm. 2021;43:11\u201324.","journal-title":"Int J Clin Pharm"},{"key":"3424_CR48","doi-asserted-by":"publisher","first-page":"P-386","DOI":"10.1016\/j.annonc.2023.04.442","volume":"34","author":"H Wasan","year":"2023","unstructured":"Wasan H, Lonardi S, Desai J, Folprecht G, Gallois C, Marques EP, et al. Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E mutant metastatic colorectal cancer. Ann Oncol. 2023;34:P-386.","journal-title":"Ann Oncol"},{"key":"3424_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-023-01456-y","volume":"16","author":"Q Gao","year":"2023","unstructured":"Gao Q, Yang L, Lu M, Jin R, Ye H, Ma T. The artificial intelligence and machine learning in lung cancer immunotherapy. J Hematol Oncol. 2023;16:55.","journal-title":"J Hematol Oncol"},{"key":"3424_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab271","volume":"22","author":"K Fan","year":"2021","unstructured":"Fan K, Cheng L, Li L. Artificial intelligence and machine learning methods in predicting anti-cancer drug combination effects. Brief Bioinform. 2021;22:bbab271.","journal-title":"Brief Bioinform"},{"key":"3424_CR51","doi-asserted-by":"crossref","unstructured":"Sebastian AM, Peter D. Artificial intelligence in cancer research: trends, challenges and future directions. Life (Basel). 2022;12:1991.","DOI":"10.3390\/life12121991"},{"key":"3424_CR52","unstructured":"The Patient\u2019s Company. Patients know best. 2024. https:\/\/patientsknowbest.com."},{"key":"3424_CR53","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12553-021-00628-5","volume":"12","author":"B Bruno","year":"2022","unstructured":"Bruno B, Steele S, Carbone J, Schneider K, Posk L, Rose SL. Informed or anxious: patient preferences for release of test results of increasing sensitivity on electronic patient portals. Health Technol (Berl). 2022;12:59\u201367.","journal-title":"Health Technol (Berl)"},{"key":"3424_CR54","doi-asserted-by":"publisher","first-page":"e32609","DOI":"10.2196\/32609","volume":"7","author":"AD Santos","year":"2021","unstructured":"Santos AD, Caine V, Robson PJ, Watson L, Easaw JC, Petrovskaya O. Oncology patients\u2019 experiences with novel electronic patient portals to support care and treatment: Qualitative study with early users and nonusers of portals in alberta, canada. JMIR Cancer. 2021;7:e32609.","journal-title":"JMIR Cancer"},{"key":"3424_CR55","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1200\/JOP.2016.011098","volume":"12","author":"M Winget","year":"2016","unstructured":"Winget M, Haji-Sheikhi F, Brown-Johnson C, Rosenthal EL, Sharp C, Buyyounouski MK, et al. Electronic release of pathology and radiology results to patients: Opinions and experiences of oncologists. J Oncol Pr. 2016;12:e792\u2013799.","journal-title":"J Oncol Pr"},{"key":"3424_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jclinepi.2023.01.011","volume":"156","author":"L Uttley","year":"2023","unstructured":"Uttley L, Quintana DS, Montgomery P, Carroll C, Page MJ, Falzon L, et al. The problems with systematic reviews: a living systematic review. J Clin Epidemiol. 2023;156:30\u201341.","journal-title":"J Clin Epidemiol"},{"key":"3424_CR57","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41591-022-01788-1","volume":"28","author":"O Mir","year":"2022","unstructured":"Mir O, Ferrua M, Fourcade A, Mathivon D, Duflot-Boukobza A, Dumont S, et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: The randomized phase 3 CAPRI trial. Nat Med. 2022;28:1224\u201331.","journal-title":"Nat Med"},{"key":"3424_CR58","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ijrobp.2022.09.078","volume":"115","author":"P Holch","year":"2023","unstructured":"Holch P, Absolom KL, Henry AM, Walker K, Gibson A, Hudson E, et al. Online symptom monitoring during pelvic radiation therapy: randomized pilot trial of the eRAPID intervention. Int J Radiat Oncol Biol Phys. 2023;115:664\u201376.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3424_CR59","doi-asserted-by":"publisher","first-page":"e44533","DOI":"10.2196\/44533","volume":"9","author":"MR LeBlanc","year":"2023","unstructured":"LeBlanc MR, LeBlanc TW, Yang Q, McLaughlin J, Irish K, Smith SK. A mobile app to support self-management in patients with multiple myeloma or chronic lymphocytic leukemia: Pilot randomized controlled trial. JMIR Cancer. 2023;9:e44533.","journal-title":"JMIR Cancer"},{"key":"3424_CR60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00520-023-07779-3","volume":"31","author":"M Lee","year":"2023","unstructured":"Lee M, Kang D, Kang E, Kim S, Kim Y, Ahn JS, et al. Efficacy of the PRO-CTCAE mobile application for improving patient participation in symptom management during cancer treatment: A randomized controlled trial. Supportive Care Cancer. 2023;31:321.","journal-title":"Supportive Care Cancer"},{"key":"3424_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09153-9","volume":"23","author":"L Verweij","year":"2023","unstructured":"Verweij L, Ector GICG, Smit Y, van Vlijmen B, van der Reijden BA, Hermens RPMG, et al. Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial. BMC Health Serv Res. 2023;23:228.","journal-title":"BMC Health Serv Res"},{"key":"3424_CR62","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1002\/cncr.34409","volume":"128","author":"JM Jacobs","year":"2022","unstructured":"Jacobs JM, Post K, Massad K, Horick NK, Walsh EA, Cohn J, et al. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: a randomized controlled trial. Cancer. 2022;128:3541\u201351.","journal-title":"Cancer"},{"key":"3424_CR63","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/pon.5701","volume":"30","author":"EK Tagai","year":"2021","unstructured":"Tagai EK, Miller SM, Hudson SV, Diefenbach MA, Handorf E, Bator A, et al. Improved cancer coping from a web-based intervention for prostate cancer survivors: a randomized controlled trial. Psychooncology. 2021;30:1466\u201375.","journal-title":"Psychooncology"},{"key":"3424_CR64","first-page":"133","volume":"18","author":"JA Greer","year":"2020","unstructured":"Greer JA, Jacobs JM, Pensak N, Nisotel LE, Fishbein JN, MacDonald JJ, et al. Randomized trial of a smartphone mobile app to improve symptoms and adherence to oral therapy for cancer. J Natl Compr Canc Netw. 2020;18:133\u201341.","journal-title":"J Natl Compr Canc Netw"},{"key":"3424_CR65","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.clbc.2020.01.004","volume":"20","author":"S Handa","year":"2020","unstructured":"Handa S, Okuyama H, Yamamoto H, Nakamura S, Kato Y. Effectiveness of a smartphone application as a support tool for patients undergoing breast cancer chemotherapy: a randomized controlled trial. Clin Breast Cancer. 2020;20:201\u20138.","journal-title":"Clin Breast Cancer"},{"key":"3424_CR66","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/pon.5489","volume":"29","author":"A Hauffman","year":"2020","unstructured":"Hauffman A, Alfonsson S, Bill-Axelson A, Bergkvist L, Forslund M, Mattsson S, et al. Cocreated internet-based stepped care for individuals with cancer and concurrent symptoms of anxiety and depression: results from the U-CARE AdultCan randomized controlled trial. Psychooncology. 2020;29:2012\u20138.","journal-title":"Psychooncology"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03424-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T09:04:19Z","timestamp":1747127059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03424-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":66,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["3424"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03424-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Graham Ferrier and Faisal Mehmud are employed by Pfizer at the time of review and writing of the manuscript. Alessandra di Pietro is employed by Pfizer at the time of review and writing of the manuscript, and also owns stocks as part of her compensation. Deepali Mittal, Geetanjali Kamath, and Saifuddin Kharawala are employees of Bridge Medical Consulting, commissioned by Pfizer to carry out this literature review. Harpreet Wasan has acted on advisory boards or as an invited speaker or has attended meetings for Servier, Pierre Fabre, Incyte, Bayer, Pfizer, Zymeworks, Merck KGaA, Taiho, Seagen, Exact therapeutics, Takeda (Hutchinson Med), Amgen, Roche\/Genentech\/ FM, SIRTEX Medical, Erytech Pharma, BMS (Celgene), and BTG; has acted in a consultancy or advisory capacity for NICE\/BSI expert Takeda, Bayer, Pierre Fabre, ONCOSIL, Incyte, Celgene, Oaktree life sciences; has served on Global Trials committees for Pfizer (Array); Zymeworks, Boehringer Ingelheim (DMC), SIRTEX, Merck KGaA, ARCAD (Pancreas Academic); and has received research funding from MSD, Merck Serono, Pfizer, and Sirtex. Aleksandra Filipovic has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}